

# Cardamom and Topical Roseomonas in Atopic Dermatitis

NCT06096857

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 2
<b>Sponsor</b>	National Institute of Allergy and Infectious Diseases (NIAID)
<b>Enrollment</b>	120 participants

## Key Eligibility Criteria

---

### Inclusion (39)

- To be eligible to participate in this study, an individual must meet all of the following criteria:
  - Aged  $\geq 2$  years
  - Have a documented primary care provider near residence
  - Fluency in English (applicable to participant or caregiver who will be answering questionnaires)
  - Clinical diagnosis of AD, as defined by Hanifin and Rajka criteria, that has been present for  $\geq 3$  months before the screening visit
- ... and 34 more (see full listing online)

### Exclusion (19)

- Previous treatment of AD:
  - Within 4 weeks prior to the baseline visit with any of the following:
  - Immunosuppressive or immunomodulating systemic drugs such as systemic corticosteroids, azathioprine, methotrexate, cyclosporine
  - Phototherapy or photochemotherapy for AD
  - Within 12 weeks prior to the baseline visit with any of the following having been newly initiated:
- ... and 14 more (see full listing online)

## Locations (1 total)

---

National Institutes of Health Clinical Center, Bethesda, Maryland, United States